Trials / Completed
CompletedNCT03081715
PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
Safety and Activity of Programmed Cell Death-1 Knockout Engineered T Cells in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma: An Open-label, Single-arm Phase 1 Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Hangzhou Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating advanced esophageal cancer. Blood or tissue samples will also be collected for research purposes.
Detailed description
This is a prospective clinical study of ex-vivo selected, engineered, and expanded PD-1 knockout T cells from autologous origin. 16 advanced esophageal cancer patients are planned to receive two cycles of PD-1 knockout engineered T cells infusion. Immunological markers are analyzed as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PD-1 Knockout T Cells | Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 |
Timeline
- Start date
- 2017-03-14
- Primary completion
- 2018-01-23
- Completion
- 2018-02-28
- First posted
- 2017-03-16
- Last updated
- 2019-06-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03081715. Inclusion in this directory is not an endorsement.